AltheRx Pharmaceuticals

AltheRx acquires Solabegron from GSK

Tuesday, March 29, 2011

AltheRx, a privately-held clinical development company, has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in phase II clinical programs for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron also demonstrated a favorable tolerability profile across all phase II studies.

[Read More]